Authors: Meng L; Department of Radiology, Chinese People's Armed Police (PAP) Hospital of Beijing, Beijing, China., Wang Z; Department of Radiology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China., Hou Z; Department of Radiology, Chinese People's Armed Police (PAP) Hospital of Beijing, Beijing, China., Wang H; National Laboratory for Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China., Zhang X; Department of Radiology, Chinese People's Armed Police (PAP) Hospital of Beijing, Beijing, China., Zhang X; Department of Radiology, Chinese People's Armed Police (PAP) Hospital of Beijing, Beijing, China., He X; Department of Radiology, Chinese People's Armed Police (PAP) Hospital of Beijing, Beijing, China., Zhang X; Department of Radiology, Chinese People's Armed Police (PAP) Hospital of Beijing, Beijing, China., Qin B; Department of Oncology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China., Li J; Department of Radiology, Characteristic Medical Center, Chinese People's Armed Police Force, Tianjin, China., Zhang Z; Department of Radiology, Chinese People's Armed Police (PAP) Hospital of Beijing, Beijing, China., Xue X; Department of Radiology, Chinese People's Armed Police (PAP) Hospital of Beijing, Beijing, China., Wei Y; Department of Radiology, Chinese People's Armed Police (PAP) Hospital of Beijing, Beijing, China.

Source: Frontiers in immunology [Front Immunol] 2022 Dec 20; Vol. 13, pp. 1064047. Date of Electronic Publication: 2022 Dec 20 (Print Publication: 2022).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH Terms: Immunotherapy*/methods , Tumor Microenvironment*, Animals ; Mice ; Epirubicin/therapeutic use ; Programmed Cell Death 1 Receptor/metabolism ; Delayed-Action Preparations/pharmacology ; Neoplasm Recurrence, Local ; Drug Carriers/pharmacology ; Hydrogels/pharmacology

Authors: Wang H; Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu,  China., Xu Y; Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu,  China., Zuo F; Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu,  China., Liu J; West China School of Medicine, West China Hospital of Sichuan University, Chengdu,  China., Yang J; Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu,  China.; Breast Center, West China Hospital of Sichuan University, Chengdu,  China.

Source: Frontiers in immunology [Front Immunol] 2022 Dec 15; Vol. 13, pp. 1020290. Date of Electronic Publication: 2022 Dec 15 (Print Publication: 2022).

Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH Terms: Immunotherapy* , Esophageal Neoplasms*, Humans ; Combined Modality Therapy ; Antibodies, Monoclonal/therapeutic use ; Molecular Targeted Therapy

Authors: Poon AYC; School of Biomedical Science, University of Hong Kong, 21 Sassoon Rd, Hong Kong999077., Sugimura R; School of Biomedical Science, University of Hong Kong, 21 Sassoon Rd, Hong Kong999077.

Source: Biology open [Biol Open] 2022 Dec 15; Vol. 11 (12). Date of Electronic Publication: 2022 Nov 29.

Publication Type: Review; Journal Article

Journal Info: Publisher: Company of Biologists Ltd Country of Publication: England NLM ID: 101578018 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2046-6390 (Electronic) Linking ISSN: 20466390 NLM ISO Abbreviation: Biol Open Subsets: MEDLINE

MeSH Terms: Immunotherapy* , Neoplasms*/therapy, Humans ; Killer Cells, Natural ; Cytokines ; Genetic Engineering

Transliterated Title: 舌下免疫治疗过敏性疾病患儿的人口学特征与依从性分析.

Authors: Huang RR; Department of Respiratory Medicine, Children's Hospital of Jiangxi Province/School of Pediatrics, Nanchang University,Nanchang,China,330000., Zhu XH; Department of Respiratory Medicine, Children's Hospital of Jiangxi Province/School of Pediatrics, Nanchang University,Nanchang,China,330000., Wang JL; Department of Respiratory Medicine, Children's Hospital of Jiangxi Province/School of Pediatrics, Nanchang University,Nanchang,China,330000.

Source: Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics [Zhongguo Dang Dai Er Ke Za Zhi] 2022 Dec 15; Vol. 24 (12), pp. 1371-1375.

Publication Type: English Abstract; Journal Article

Journal Info: Publisher: Zhongguo dang dai er ke za zhi she Country of Publication: China NLM ID: 100909956 Publication Model: Print Cited Medium: Print ISSN: 1008-8830 (Print) Linking ISSN: 10088830 NLM ISO Abbreviation: Zhongguo Dang Dai Er Ke Za Zhi Subsets: MEDLINE

MeSH Terms: Sublingual Immunotherapy* , Rhinitis, Allergic*/therapy, Male ; Animals ; Female ; Humans ; Child ; Child, Preschool ; Adolescent ; Retrospective Studies ; Pyroglyphidae ; Treatment Outcome ; Demography ; Allergens

Authors: Núñez R; Laboratory of Allergy, Allergy Research Group, Instituto de Investigación Biomédica de Málaga-Plataforma Andalusian Centre for Nanomedicine and Biotechnology (IBIMA-BIONAND), Málaga, Spain., Rodríguez MJ; Laboratory of Allergy, Allergy Research Group, Instituto de Investigación Biomédica de Málaga-Plataforma Andalusian Centre for Nanomedicine and Biotechnology (IBIMA-BIONAND), Málaga, Spain., Lebrón-Martín C; Laboratory of Allergy, Allergy Research Group, Instituto de Investigación Biomédica de Málaga-Plataforma Andalusian Centre for Nanomedicine and Biotechnology (IBIMA-BIONAND), Málaga, Spain., Martín-Astorga MDC; Laboratory of Allergy, Allergy Research Group, Instituto de Investigación Biomédica de Málaga-Plataforma Andalusian Centre for Nanomedicine and Biotechnology (IBIMA-BIONAND), Málaga, Spain.; Department of Medicine, Universidad de Málaga (UMA), Málaga, Spain., Palomares F; Laboratory of Allergy, Allergy Research Group, Instituto de Investigación Biomédica de Málaga-Plataforma Andalusian Centre for Nanomedicine and Biotechnology (IBIMA-BIONAND), Málaga, Spain., Ramos-Soriano J; Laboratory of Glycosystems, Institute of Chemical Research (IIQ), Spanish National Research Council (CSIC)- Universidad de Sevilla, Sevilla, Spain., Rojo J; Laboratory of Glycosystems, Institute of Chemical Research (IIQ), Spanish National Research Council (CSIC)- Universidad de Sevilla, Sevilla, Spain., Torres MJ; Laboratory of Allergy, Allergy Research Group, Instituto de Investigación Biomédica de Málaga-Plataforma Andalusian Centre for Nanomedicine and Biotechnology (IBIMA-BIONAND), Málaga, Spain.; Department of Medicine, Universidad de Málaga (UMA), Málaga, Spain.; Clinical Unit of Allergy, Hospital Regional Universitario de Málaga, Málaga, Spain., Cañas JA; Laboratory of Allergy, Allergy Research Group, Instituto de Investigación Biomédica de Málaga-Plataforma Andalusian Centre for Nanomedicine and Biotechnology (IBIMA-BIONAND), Málaga, Spain., Mayorga C; Laboratory of Allergy, Allergy Research Group, Instituto de Investigación Biomédica de Málaga-Plataforma Andalusian Centre for Nanomedicine and Biotechnology (IBIMA-BIONAND), Málaga, Spain.; Clinical Unit of Allergy, Hospital Regional Universitario de Málaga, Málaga, Spain.

Source: Frontiers in immunology [Front Immunol] 2022 Dec 14; Vol. 13, pp. 1094172. Date of Electronic Publication: 2022 Dec 14 (Print Publication: 2022).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH Terms: Food Hypersensitivity* , Sublingual Immunotherapy* , Anaphylaxis*, Animals ; Mice ; Methylation ; Allergens ; Desensitization, Immunologic

Authors: Balta E; Section of Molecular Immunology, Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany., Janzen N; Section of Molecular Immunology, Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany., Kirchgessner H; Section of Molecular Immunology, Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany., Toufaki V; Section of Molecular Immunology, Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany., Orlik C; Section of Molecular Immunology, Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany., Liang J; Section of Molecular Immunology, Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany., Lairikyengbam D; Section of Molecular Immunology, Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany., Abken H; Leibniz Institute for Immunotherapy, Division of Genetic Immunotherapy, University Regensburg, Regensburg, Germany., Niesler B; Department of Human Molecular Genetics, Heidelberg University Hospital, Heidelberg, Germany.; Counter Core Facility, Institute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany., Müller-Decker K; Core Facility Tumor Models, German Cancer Research Center, Heidelberg, Germany., Ruppert T; Mass Spectrometry Core Facility, Center for Molecular Biology, Heidelberg University, Heidelberg, Germany., Samstag Y; Section of Molecular Immunology, Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany.

Source: Frontiers in immunology [Front Immunol] 2022 Dec 14; Vol. 13, pp. 1063313. Date of Electronic Publication: 2022 Dec 14 (Print Publication: 2022).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH Terms: Immunotherapy, Adoptive*/methods , Neoplasms*/immunology , Neoplasms*/therapy , Oxidative Stress*/genetics , Oxidative Stress*/immunology , T-Lymphocytes*/immunology , Tumor Microenvironment*/genetics , Tumor Microenvironment*/immunology, Humans ; Antioxidants/metabolism ; Oxidation-Reduction ; Thioredoxins/genetics ; Thioredoxins/immunology

Authors: Woo SM; Department of Gastroenterology and Hepatology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Washington, DC 20007, USA., Kimchy AV; Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC 20007, USA., Sequeira LM; Georgetown University School of Medicine, Washington, DC 20007, USA., Dorris CS; Dahlgren Memorial Library, Georgetown University Medical Center, Washington, DC 20007, USA., He AR; Department of Hematology and Oncology, MedStar Georgetown University Hospital, Washington, DC 20007, USA., Rangnekar AS; MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC 20007, USA.

Source: Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Dec 13; Vol. 29 (12), pp. 9813-9825. Date of Electronic Publication: 2022 Dec 13.

Publication Type: Journal Article; Review

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE

MeSH Terms: B7-H1 Antigen*/metabolism , Carcinoma, Hepatocellular*/surgery , Immunotherapy*/methods , Liver Neoplasms*/surgery , Liver Transplantation* , Graft Rejection*/diagnosis , Graft Rejection*/prevention & control, Humans ; Programmed Cell Death 1 Receptor/metabolism ; United States

Authors: Davey BC; Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, United States., Pampusch MS; Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, United States., Cartwright EK; Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, United States., Abdelaal HM; Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, United States., Rakasz EG; Wisconsin National Primate Research Center, University of Wisconsin, Madison, Madison, WI, United States., Rendahl A; Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, United States., Berger EA; Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States., Skinner PJ; Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN, United States.

Source: Frontiers in immunology [Front Immunol] 2022 Dec 13; Vol. 13, pp. 1032537. Date of Electronic Publication: 2022 Dec 13 (Print Publication: 2022).

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH Terms: Receptors, Chimeric Antigen* , Simian Acquired Immunodeficiency Syndrome*/therapy , Immunotherapy*, Animals ; Antibodies/therapeutic use ; Antibody Formation ; CD28 Antigens ; Macaca mulatta ; Simian Immunodeficiency Virus

Authors: Parsonidis P; Research Genetic Cancer Centre S.A., Florina, Greece., Beis G; Research Genetic Cancer Centre S.A., Florina, Greece., Iliopoulos AC; Research Genetic Cancer Centre S.A., Florina, Greece., Papasotiriou I; Research Genetic Cancer Centre International GmbH, Zug, Switzerland. Electronic address: papasotiriou.ioannis@rgcc-international.com.

Source: Cellular immunology [Cell Immunol] 2022 Dec; Vol. 382, pp. 104616. Date of Electronic Publication: 2022 Sep 27.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 1246405 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1090-2163 (Electronic) Linking ISSN: 00088749 NLM ISO Abbreviation: Cell Immunol Subsets: MEDLINE

MeSH Terms: Immunotherapy, Adoptive*/methods , Neoplasms*/therapy, Humans ; Epithelial Cell Adhesion Molecule ; Killer Cells, Natural ; T-Lymphocytes, Cytotoxic

Authors: Pettinger C; Drug Development Unit, Royal Marsden NHS Foundation Trust, London, UK.; Division of Clinical Studies, Institute of Cancer Research, London, UK., Livings C; Drug Development Unit, Royal Marsden NHS Foundation Trust, London, UK.; Division of Clinical Studies, Institute of Cancer Research, London, UK., Grochot R; Drug Development Unit, Royal Marsden NHS Foundation Trust, London, UK.; Division of Clinical Studies, Institute of Cancer Research, London, UK., Furness A; Renal, Skin & Cell Therapy, Royal Marsden NHS Foundation Trust, London, UK., Lopez J; Drug Development Unit, Royal Marsden NHS Foundation Trust, London, UK juanita.lopez@icr.ac.uk.; Division of Clinical Studies, Institute of Cancer Research, London, UK.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Dec; Vol. 10 (12).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

MeSH Terms: Immunotherapy* , Neoplasms*/therapy, Humans ; Cytokines/metabolism ; Health Services

Authors: Sly LM; Division of Gastroenterology, Department of Pediatrics, University of British Columbia and BC Children's Research Institute, Vancouver, BC, Canada. Electronic address: laura.sly@ubc.ca., McKay DM; Gastrointestinal Research Group, Inflammation Research Network, Host-Parasite Interactions Group, Department of Physiology and Pharmacology, Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada. Electronic address: dmckay@ucalgary.ca.

Source: Trends in immunology [Trends Immunol] 2022 Dec; Vol. 43 (12), pp. 959-968. Date of Electronic Publication: 2022 Oct 29.

Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 100966032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-4981 (Electronic) Linking ISSN: 14714906 NLM ISO Abbreviation: Trends Immunol Subsets: MEDLINE

MeSH Terms: Immunologic Factors* , Immunotherapy*, Animals ; Humans ; Macrophages ; Precision Medicine ; Leukocyte Count ; Mammals

Authors: Wang X; Precision Medicine Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Wu C; Precision Medicine Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Wei H; Precision Medicine Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Source: Antioxidants & redox signaling [Antioxid Redox Signal] 2022 Dec; Vol. 37 (16-18), pp. 1291-1302. Date of Electronic Publication: 2022 Sep 07.

Publication Type: Journal Article; Review

Journal Info: Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 100888899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-7716 (Electronic) Linking ISSN: 15230864 NLM ISO Abbreviation: Antioxid Redox Signal Subsets: MEDLINE

MeSH Terms: Neoplasms*/therapy , Immunotherapy*, Animals ; Humans ; Mice

Authors: Vogelberg C; Department of Pediatric Pneumology and Allergology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany., Klimek L; Center for Rhinology and Allergology, Wiesbaden, Germany., Brüggenjürgen B; Institute for Healthcare Research and Technical Orthopedics, Medical University, Hannover, Germany., Jutel M; All-MED Medical Research Institute, Wrocław, Poland.; Department of Clinical Immunology, Wroclaw Medical University, Wrocław, Poland.

Source: Allergy [Allergy] 2022 Dec; Vol. 77 (12), pp. 3584-3592. Date of Electronic Publication: 2022 Sep 19.

Publication Type: Journal Article; Review

Journal Info: Publisher: Wiley-Blackwell Country of Publication: Denmark NLM ID: 7804028 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1398-9995 (Electronic) Linking ISSN: 01054538 NLM ISO Abbreviation: Allergy Subsets: MEDLINE

MeSH Terms: Rhinitis, Allergic*/therapy , Sublingual Immunotherapy*/methods , Asthma*/therapy, Humans ; Desensitization, Immunologic/methods ; Allergens

Authors: Haanen J; Division of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands., Obeid M; Immunology and Allergy Service, CHUV, Lausanne; Lausanne Center for Immuno-oncology Toxicities (LCIT), CHUV, Lausanne; Department of Oncology, CHUV, Lausanne, Switzerland., Spain L; Medical Oncology Department, Peter MacCallum Cancer Centre, Melbourne; Department of Medical Oncology, Eastern Health, Melbourne; Monash University Eastern Health Clinical School, Box Hill, Australia., Carbonnel F; Gastroenterology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, Le Kremlin Bicêtre, France; Université Paris Saclay 11, Le Kremlin-Bicêtre, France., Wang Y; Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, USA., Robert C; Department of Medicine, Gustave Roussy Cancer Centre, Villejuif; Paris-Saclay University, Villejuif, France., Lyon AR; Cardio-Oncology Service, Royal Brompton Hospital, London; National Heart and Lung Institute, Imperial College London, London, UK., Wick W; Neurology Clinic and National Centre for Tumour Diseases, University Hospital Heidelberg, Heidelberg; DKTK and Clinical Cooperation Unit NeuroOncology, DKFZ, Heidelberg, Germany., Kostine M; Department of Rheumatology, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France., Peters S; Department of Oncology, CHUV, Lausanne, Switzerland., Jordan K; Department of Haematology, Oncology and Palliative Medicine, Ernst von Bergmann Hospital Potsdam, Potsdam; Department of Haematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany., Larkin J; Royal Marsden NHS Foundation Trust, London, UK.

Corporate Authors: ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2022 Dec; Vol. 33 (12), pp. 1217-1238. Date of Electronic Publication: 2022 Oct 18.

Publication Type: Practice Guideline; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

MeSH Terms: Immunotherapy*/adverse effects , Immunologic Factors*, Humans ; Follow-Up Studies

Authors: Yuan H; Department of Pharmacy, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, 24 Jinghua Road, Jianxi District, Luoyang 471003, China., Duan DD; Henan Provincial Corps Hospital of Chinese People's Armed Police Force, Zhengzhou 450000, China., Zhang YJ; Department of Pharmacy, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, 24 Jinghua Road, Jianxi District, Luoyang 471003, China. Electronic address: xiahuayouyou@126.com.

Source: Clinics and research in hepatology and gastroenterology [Clin Res Hepatol Gastroenterol] 2022 Dec; Vol. 46 (10), pp. 102031. Date of Electronic Publication: 2022 Oct 17.

Publication Type: Journal Article; Meta-Analysis; Systematic Review

Journal Info: Publisher: Elsevier Masson Country of Publication: France NLM ID: 101553659 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2210-741X (Electronic) Linking ISSN: 22107401 NLM ISO Abbreviation: Clin Res Hepatol Gastroenterol Subsets: MEDLINE

MeSH Terms: Immunotherapy*/adverse effects , Stomach Neoplasms*/drug therapy, Female ; Humans ; Esophagogastric Junction ; Immune Checkpoint Inhibitors ; Immunologic Factors/therapeutic use ; Randomized Controlled Trials as Topic ; Male

Authors: Bozek A; Clinical Department of Internal Diseases, Dermatology and Allergology in Zabrze, Medical University of Silesia, Katowice, Poland., Kozłowska R; Clinical Department of Internal Diseases, Dermatology and Allergology in Zabrze, Medical University of Silesia, Katowice, Poland., Misiołek M; Department of Otorhinolaryngology and Laryngological Oncology in Zabrze, Medical University of Silesia, Katowice, Poland., Ścierski W; Department of Otorhinolaryngology and Laryngological Oncology in Zabrze, Medical University of Silesia, Katowice, Poland., Gawlik R; Clinical Department of Internal Diseases, Allergology and Clinical Immunology in Zabrze, Medical University of Silesia, Katowice, Poland.

Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2022 Nov 30; Vol. 18 (6), pp. 2097818. Date of Electronic Publication: 2022 Jul 11.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

MeSH Terms: Rhinitis, Allergic*/therapy , Sublingual Immunotherapy*/methods , Rhinitis*, Animals ; Humans ; Pyroglyphidae ; Antigens, Dermatophagoides/therapeutic use ; Omalizumab/therapeutic use ; Desensitization, Immunologic/methods ; Tablets ; Treatment Outcome ; Allergens

Authors: Sun X; State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Peking University, Beijing, China., Zhang Z; Department of Pharmacy, Peking University First Hospital, Beijing, China.; Institute of Clinical Pharmacology, Peking University, Beijing, China., Wang Z; State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Peking University, Beijing, China., Xie R; Department of Pharmacy, Peking University First Hospital, Beijing, China., Yi C; State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Peking University, Beijing, China., Liu H; Departments of Otorhinolaryngology-Head and Neck Surgery, Peking University First Hospital, Beijing, China., Chi X; State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Peking University, Beijing, China., Li T; Departments of Otorhinolaryngology-Head and Neck Surgery, Peking University First Hospital, Beijing, China., Liu H; Institute of Clinical Pharmacology, Peking University, Beijing, China., Han Y; Department of Thoracic Surgery, Beijing Thoracic Hospital, Beijing, China., Pang X; Department of Pharmacy, Peking University First Hospital, Beijing, China.; Institute of Clinical Pharmacology, Peking University, Beijing, China., Cui Y; Department of Pharmacy, Peking University First Hospital, Beijing, China.; Institute of Clinical Pharmacology, Peking University, Beijing, China., Liu Z; State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Peking University, Beijing, China.

Source: Frontiers in immunology [Front Immunol] 2022 Nov 21; Vol. 13, pp. 1033967. Date of Electronic Publication: 2022 Nov 21 (Print Publication: 2022).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH Terms: Immunotherapy* , Urinary Bladder Neoplasms*, Humans ; Prognosis ; Tumor Microenvironment/genetics ; Cardiovascular Physiological Phenomena

Authors: Minott JA; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., van Vloten JP; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Yates JGE; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Chan L; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Wood GA; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Viloria-Petit AM; Department of Biomedical Sciences, University of Guelph, Guelph, ON, Canada., Karimi K; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Petrik JJ; Department of Biomedical Sciences, University of Guelph, Guelph, ON, Canada., Wootton SK; Department of Pathobiology, University of Guelph, Guelph, ON, Canada., Bridle BW; Department of Pathobiology, University of Guelph, Guelph, ON, Canada.; ImmunoCeutica Inc., Cambridge, ON, Canada.

Source: Frontiers in immunology [Front Immunol] 2022 Nov 16; Vol. 13, pp. 1038340. Date of Electronic Publication: 2022 Nov 16 (Print Publication: 2022).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

MeSH Terms: Immunotherapy* , Neoplasms*/therapy, Humans ; Flow Cytometry ; Antibodies ; Biological Assay

Authors: Le Q; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Hadland B; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Pediatrics, University of Washington, Seattle, Washington, USA., Smith JL; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Leonti A; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Huang BJ; Department of Pediatrics and.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Ries R; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Hylkema TA; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Castro S; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Tang TT; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., McKay CN; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Perkins L; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Pardo L; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Sarthy J; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Beckman AK; Department of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, Minnesota, USA., Williams R; Department of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, Minnesota, USA., Idemmili R; Department of Laboratory Medicine & Pathology, University of Minnesota, Minneapolis, Minnesota, USA., Furlan S; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Ishida T; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Call L; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Srivastava S; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Loeb AM; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Milano F; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Imren S; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Morris SM; Seattle Children's Research Institute, Seattle, Washington, USA., Pakiam F; Seattle Children's Research Institute, Seattle, Washington, USA., Olson JM; Seattle Children's Research Institute, Seattle, Washington, USA., Loken MR; Hematologics, Inc, Seattle, Washington, USA., Brodersen L; Hematologics, Inc, Seattle, Washington, USA., Riddell SR; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Tarlock K; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Pediatrics, University of Washington, Seattle, Washington, USA., Bernstein ID; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Pediatrics, University of Washington, Seattle, Washington, USA., Loeb KR; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA., Meshinchi S; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; Department of Pediatrics, University of Washington, Seattle, Washington, USA.; Children's Oncology Group, Monrovia, California, USA.

Source: The Journal of clinical investigation [J Clin Invest] 2022 Nov 15; Vol. 132 (22). Date of Electronic Publication: 2022 Nov 15.

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE

MeSH Terms: Folate Receptor 1*/genetics , Folate Receptor 1*/metabolism , Immunotherapy, Adoptive* , Leukemia, Megakaryoblastic, Acute*/genetics , Oncogene Proteins, Fusion*/genetics , Oncogene Proteins, Fusion*/metabolism, Animals ; Child ; Child, Preschool ; Humans ; Infant ; Disease Models, Animal ; T-Lymphocytes ; Transcriptome ; Xenograft Model Antitumor Assays

Authors: Zhang R; College of life science and technology, Beijing University of Chemical Technology, 15 Beisanhuan East Road, Chaoyang District, Beijing 100029, P.R. China., Zhang J; Biocytogen Pharmaceuticals (Beijing) Co., Ltd., 12 Baoshen South Street, Daxing District,102609, Beijing, P.R. China., Zhou X; Biocytogen Pharmaceuticals (Beijing) Co., Ltd., 12 Baoshen South Street, Daxing District,102609, Beijing, P.R. China., Zhao A; Biocytogen Pharmaceuticals (Beijing) Co., Ltd., 12 Baoshen South Street, Daxing District,102609, Beijing, P.R. China., Yu C; College of life science and technology, Beijing University of Chemical Technology, 15 Beisanhuan East Road, Chaoyang District, Beijing 100029, P.R. China.

Source: Experimental animals [Exp Anim] 2022 Nov 10; Vol. 71 (4), pp. 442-450. Date of Electronic Publication: 2022 May 13.

Publication Type: Journal Article

Journal Info: Publisher: Japanese Association for Laboratory Animal Science Country of Publication: Japan NLM ID: 9604830 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1881-7122 (Electronic) Linking ISSN: 00075124 NLM ISO Abbreviation: Exp Anim Subsets: MEDLINE

MeSH Terms: Immunotherapy*/methods , Neoplasms*/drug therapy, Mice ; Humans ; Animals ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal/pharmacology ; Disease Models, Animal ; CD3 Complex